首页 > 市场调查报告书 > 製药

感染疾病

市场调查报告书

商品编码

1084773

肝炎治疗药的世界市场规模、占有率、展望、机会分析 (2022年～2028年):各药物类别、疾病类型、给药途径、流通管道、地区

Global Hepatitis Drugs Market, By Drug Class, By Disease Type, By Route of Administration, By Distribution Channel, and By Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

出版日期: 2022年05月10日 | 出版商:

Coherent Market Insights | 英文 173 Pages | 商品交期: 2-3个工作天内

价格

简介目录

全球的肝炎增加支援肝炎治疗药市场成长。预计同时，对于肝炎治疗药的开发、核准需要的时间长度等妨碍在预测期间内的市场成长。

本报告提供全球肝炎治疗药的市场调查，市场定义和概要，市场成长的各种影响因素分析，法律制度，偿付情境，市场规模的变化、预测，各种区分、各地区/主要国家的明细，竞争环境，主要企业简介等彙整资讯。

Hepatitis refers to an inflammatory condition of the liver. Viral infections of the liver classified as hepatitis include hepatitis A, B, C, D, and E. Hepatitis A is an acute, short-term disease, while hepatitis B, C, and D are most likely to become ongoing and chronic. Hepatitis E is usually acute but can be particularly dangerous in pregnant women which increase maternal and fetal mortality and morbidity.

Market Dynamics

Increasing prevalence of hepatitis worldwide is expected to boost growth of the hepatitis drugs market. According to World Health Organization (WHO), in 2015, 257 million people were living with chronic hepatitis B infection, and in 2016, while 4.5 million (16.7%) of the people were diagnosed with hepatitis B . Hepatitis B can be prevented by safe and effective vaccines. Additionally, the WHO aims for eliminating viral hepatitis infections which include 90% reduction of new infections, 65% reduction in deaths resulting from viral hepatitis infections worldwide by 2030.

However, factors such as longer development and approval time for hepatitis drugs is expected to hinder growth of the hepatitis drugs market during the forecast period. For instance, according to the National Center for Biotechnology Information 2017, the development of a new medicine for hepatitis from target identification through approval for marketing, takes 12 years or longer.

Key features of the study:

This report provides in-depth analysis of the hepatitis drugs market, market size (US$ Mn), and Compound Annual Growth Rate (CAGR (%)) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
It profiles key players in the global hepatitis drugs market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
Key players covered as a part of this study include Merck & Co. Inc., Gilead Sciences Inc., AbbVie Inc., Bristol Myers Squibb Company, F. Hoffmann-La Roche Ltd., LAURUS Labs, Zydus Cadila, Hetero Healthcare Limited, GlaxoSmithKline PLC., and Cipla Inc.
Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
The global hepatitis drugs market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for hepatitis drugs market, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:

Global Hepatitis Drugs Market, By Drug Class:
- Interferon Alphas
- HIV NRTIs
- Nucleotide Polymerase / NS5A Inhibitor Combinations
- Hepatitis C Protease / NS5A Inhibitor Combinations
- NS5A Inhibitors
- Nucleotide Polymerase Inhibitors
- Nucleoside Analogue Antivirals
- Thrombopoiesis Stimulating Agents
Global Hepatitis Drugs Market, By Disease Type:
- Hepatitis B
- Hepatitis C
- Others
Global Hepatitis Drugs Market, By Route of Administration:
- Oral
- Injection
Global Hepatitis Drugs Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Hepatitis Drugs Market, By Region:
- North America
  - By Country:
- U.S.
- Canada
  - By Drug Class:
- Interferon Alphas
- HIV NRTIs
- Nucleotide Polymerase / NS5A Inhibitor Combinations
- Hepatitis C Protease / NS5A Inhibitor Combinations
- NS5A Inhibitors
- Nucleotide Polymerase Inhibitors
- Nucleoside Analogue Antivirals
- Thrombopoiesis Stimulating Agents
  - By Disease Type:
- Hepatitis B
- Hepatitis C
- Others
  - By Route of Administration:
- Oral
- Injection
  - By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Europe
  - By Country:
- U.K.
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
  - By Drug Class:
- Interferon Alphas
- HIV NRTIs
- Hepatitis B NRTIs
- Nucleotide Polymerase / NS5A Inhibitor Combinations
- Hepatitis C Protease / NS5A Inhibitor Combinations
- NS5A Inhibitors
- Nucleotide Polymerase Inhibitors
- Nucleoside Analogue Antivirals
- Thrombopoiesis Stimulating Agents
  - By Disease Type:
- Hepatitis B
- Hepatitis C
- Others
  - By Route of Administration:
- Oral
- Injection
  - By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Asia Pacific
  - By Country:
- Australia
- India
- China
- Japan
- ASEAN
- South Korea
- Rest of Asia Pacific
  - By Drug Class:
- Interferon Alphas
- HIV NRTIs
- Nucleotide Polymerase / NS5A Inhibitor Combinations
- Hepatitis C Protease / NS5A Inhibitor Combinations
- NS5A Inhibitors
- Nucleotide Polymerase Inhibitors
- Nucleoside Analogue Antivirals
- Thrombopoiesis Stimulating Agents
  - By Disease Type:
- Hepatitis B
- Hepatitis C
- Others
  - By Route of Administration:
- Oral
- Injection
  - By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Latin America
  - By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
  - By Drug Class:
- Interferon Alphas
- HIV NRTIs
- Nucleotide Polymerase / NS5A Inhibitor Combinations
- Hepatitis C Protease / NS5A Inhibitor Combinations
- NS5A Inhibitors
- Nucleotide Polymerase Inhibitors
- Nucleoside Analogue Antivirals
- Thrombopoiesis Stimulating Agents
  - By Disease Type:
- Hepatitis B
- Hepatitis C
- Others
  - By Route of Administration:
- Oral
- Injection
  - By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Middle East
  - By Country:
- GCC
- Israel
- Rest of Middle East
  - By Drug Class:
- Interferon Alphas
- HIV NRTIs
- Nucleotide Polymerase / NS5A Inhibitor Combinations
- Hepatitis C Protease / NS5A Inhibitor Combinations
- NS5A Inhibitors
- Nucleotide Polymerase Inhibitors
- Nucleoside Analogue Antivirals
- Thrombopoiesis Stimulating Agents
  - By Disease Type:
- Hepatitis B
- Hepatitis C
- Others
  - By Route of Administration:
- Oral
- Injection
  - By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Africa
  - By Country:
- South Africa
- Central Africa
- North Africa
  - By Drug Class:
- Interferon Alphas
- HIV NRTIs
- Nucleotide Polymerase / NS5A Inhibitor Combinations
- Hepatitis C Protease / NS5A Inhibitor Combinations
- NS5A Inhibitors
- Nucleotide Polymerase Inhibitors
- Nucleoside Analogue Antivirals
- Thrombopoiesis Stimulating Agents
  - By Disease Type:
- Hepatitis B
- Hepatitis C
- Others
  - By Route of Administration:
- Oral
- Injection
  - By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Company Profiles
- Merck & Co. Inc.*
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Strategies
- Gilead Sciences Inc.
- AbbVie Inc.
- Bristol Myers Squibb Company
- F. Hoffmann-La Roche Ltd.
- LAURUS Labs
- Zydus Cadila
- Hetero Healthcare Limited
- GlaxoSmithKline PLC
- Cipla Inc.

"*" marked represents similar segmentation in other categories in the respective section

1. Research Objective and Assumption

Research Objectives
Assumptions
Abbreviations

2. Market Overview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Drug Class
- Market Snippet, By Disease Type
- Market Snippet, By Route of Administration
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Market Trends
Key Developments
Regulatory Landscape
Epidemiology Analysis
Reimbursement Scenario
PEST Analysis

4. Global Hepatitis Drugs Market, By Drug Class, 2017 - 2028 (US$ Million)

Introduction
- Market Share Analysis, 2022 and 2028(%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
Interferon Alphas
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
HIV NRTIs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
Nucleotide Polymerase / NS5A Inhibitor Combinations
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
Hepatitis C Protease / NS5A Inhibitor Combinations
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
NS5A Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
Nucleotide Polymerase Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
Nucleoside Analogue Antivirals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
Thrombopoiesis Stimulating Agents
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

5. Global Hepatitis Drugs Market, By Disease Type, 2017 - 2028, (US$ Million)

Introduction
- Market Share Analysis, 2022 and 2028(%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
Hepatitis B
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
Hepatitis C
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

6. Global Hepatitis Drugs Market, By Route of Administration, 2017 - 2028, (US$ Million)

Introduction
- Market Share Analysis, 2022 and 2028(%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
Injection
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

7. Global Hepatitis Drugs Market, By Distribution Channel, 2017 - 2028, (US$ Million)

Introduction
- Market Share Analysis, 2022 and 2028(%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

8. Global Hepatitis Drugs Market, By Region, 2017 - 2028, (US$ Million)

Introduction
- Market Share Analysis, By Region, 2022 and 2028(%)
- Y-o-Y Growth Analysis, By Region, 2017 - 2028
- Regional Trends
North America
- Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Disease Type, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Route of Administration, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
- U.S.
- Canada
Europe
- Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Disease Type, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Route of Administration, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
Asia Pacific
- Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Disease Type, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Route of Administration, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
- China
- Japan
- India
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
Latin America
- Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Disease Type, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Route of Administration, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
Africa
- Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Disease Type, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Route of Administration, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
- North Africa
- Central Africa
- South Africa
Middle East
- Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Disease Type, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Route of Administration, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)l
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
- GCC Countries
- Israel
- Rest of Middle East

9. Competitive Landscape

Company Profiles
- Merck & Co. Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Gilead Sciences Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- AbbVie Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Bristol Myers Squibb Company
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- F. Hoffmann-La Roche Ltd.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- LAURUS Labs
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Zydus Cadila
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Hetero Healthcare Limited
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- GlaxoSmithKline PLC.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Cipla Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
Analyst Views

10. Section

References
Research Methodology
About Us and Sales Contact

02-2729-4219

+886-2-2729-4219

License/价格

肝炎治疗药的世界市场规模、占有率、展望、机会分析 (2022年～2028年):各药物类别、疾病类型、给药途径、流通管道、地区

Global Hepatitis Drugs Market, By Drug Class, By Disease Type, By Route of Administration, By Distribution Channel, and By Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

目录

第1章调查目的、前提条件

第2章市场概要

第3章市场动态、法律规章、趋势分析

第4章全球肝炎治疗药市场:各类药物

第5章全球肝炎治疗药市场:各疾病类型

第6章全球肝炎治疗药市场:各给药途径

第7章全球肝炎治疗药市场:各流通管道

第8章全球肝炎治疗药市场:各地区

第9章竞争情形

第10章 Section